Abstract: Eccogene is seeking to raise at least USD 100m via a Hong Kong listing. Joint sponsors are Jefferies, BOA, CICC. While our previous note covers the fundamentals of the company, in this note we look at the updates from the latest application proof. We think the deal is still worth following but June 2026 will be a binary event as the key data will be released.
Research on Hong Kong and A+H equity offerings, from the first filing to the aftermarket. Coverage includes pre-IPO early thoughts on the business and valuation, analysis of the final deal terms and cornerstone investors, and updates as new prospectus versions are filed.
Interested in the full report? Get in touch with our team.